new retatrutide 🎙️ EPISODE: Retatrutide—The Triple Agonist *Not licensed* Will this replace the current GLP-1 in the market., This triple receptor agonist (GIP/GLP-1/glucagon) is showing unprecedented results in Retatrutide Helped Adults With Diabetes

BMJ 381 , e074572 (2023)

GLP-1s are most effective when combined with healthy eating and regular exercise

We also weighed real-world feedback

Left unaddressed, these deficiencies can significantly increase the risk of falls, fractures, and long-term loss of independence in peri-menopausal women

While pharmaceutical interventions for enhancing GLP-1 activity exist, exploring natural sources offers a holistic and more sustainable approach to metabolic health

Discontinuation Rates Treatment Discontinuation Due to Adverse Events: Retatrutide 9mg: 12.2% Retatrutide 12mg: 18.2% Placebo: 4.0% Interestingly, some discontinuations were attributed to "perceived excessive weight loss" participants felt they were losing weight too rapidly or had reached their desired weight and chose to discontinue